Regenerative Cell Conditioned Media for Orthopox Virus Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies lack effective methods for preventing and treating Orthopox viruses, such as Monkeypox and Smallpox, with no specific vaccines or drugs available, posing a significant public health threat.
Innovation Solution
The use of regenerative cells, specifically mesenchymal stem cells, are stimulated with ligands for Toll-Like Receptors and their conditioned media is collected, concentrated, and administered to provide prophylaxis and treatment by enhancing immune response and producing therapeutic factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no specific vaccines or drugs are available for Orthopox viruses, then the public health threat remains high and effective prevention/treatment is lacking, but developing and implementing specific vaccines or drugs would require significant time and resources
Solution Approach 1:
The patent applies preliminary action by pre-stimulating regenerative cells with TLR ligands before administration to patients. The cells are activated in advance to produce and load antiviral factors (such as type I interferons, IL-10, TGF-β) into their secretome, ensuring immediate therapeutic effect upon injection. This pre-preparation of the therapeutic agent eliminates the need for time-consuming in vivo vaccination or drug synthesis during the outbreak response.
Solution Approach 2:
The patent extracts the therapeutic function from the entire regenerative cell system by isolating and concentrating the active secretome factors (interferons, cytokines, growth factors) into a defined therapeutic product. This extraction allows the therapeutic activity to be separated from the cells themselves, enabling standardized production, storage, and administration without requiring live cell handling, thus accelerating deployment while maintaining efficacy.
2Reliability
If regenerative cells are stimulated with TLR ligands to produce therapeutic factors, then antiviral activity is enhanced, but the complexity of cell stimulation and secretome collection increases
Solution Approach 1:
The patent uses TLR ligands as intermediary substances that bridge the gap between the administered therapy and the desired antiviral effect. These ligands (such as poly(I:C), lipopolysaccharide, or flagellin) are introduced to stimulate regenerative cells to produce and secrete antiviral factors. The ligands act as mediators that trigger the cellular response without requiring direct viral contact or complex signaling pathways, simplifying the overall system while maintaining strong antiviral activity.
Solution Approach 2:
The patent employs parameter changes by controlling the concentration, purity, and composition of the secretome through standardized cell culture conditions and centrifugation protocols. The therapeutic secretome is concentrated and purified to specific parameters (e.g., interferon activity units, cytokine ratios, protein concentration) to ensure consistent antiviral efficacy. This standardization of parameters reduces variability and simplifies quality control, making the complex cell-based therapy reproducible and scalable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively inhibits and alleviates Orthopox virus infections by leveraging the immune-modulatory and antiviral properties of regenerative cell-derived factors, offering a novel strategy for prevention and treatment.
Implementation Method 1
stimulating said regenerative cell population with a ligand for Toll-Like Receptors (TLRs)
Implementation Method 2
concentrating active ingredients from said supernatant
Data Source
AI summary
Disclosed are prophylactic and therapeutic approaches to Orthopox viral infections. In one embodiment the invention teaches utilization of regenerative cell conditioned media as a prophylactic/therapeutic agent. Synergies with antivirals and immunotherapies are further described. In one specific embodiment, mesenchymal stem cells are activated in vitro with trigger agents activating Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) and conditioned media is isolated and utilized as a therapeutic. Quantification of activity is performed by assessment of antiviral activity and/or ability to stimulate NK mediated cytolysis. Additionally, means of treating Orthopox viral infections (Smallpox, Monkeypox, etc.) by direct administration of stem cells and/or products thereof such as exosomes are disclosed.